Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices.
Mannello F, Tanus-Santos JE, Meschiari CA, Tonti GA
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to determine the effects of collection container and added silica on MMP-2 and MMP-9 levels in serum and plasma specimens.
Summary of Findings
Collection tube type and treatment with silica did not affect levels of MMP-2. Levels of MMP-9 decreased with silica treatment prior to separation of the plasma and serum, but were unaffected by addition of silica or silicate to separated plasma or serum. Plasma levels of MMP-9 were higher than levels in serum collected with clot activators. Serum collected in plastic tubes had less MMP-9 than serum collected in glass tubes.
Biospecimens
FluidPlasmaFluidSerumFluidBloodPreservation Types
None (Fresh)Diagnoses
NormalPlatforms
ProteinELISAProteinZymographyPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Type of collection container/solution GlassNatrium citrate plasma tubePlasticPlastic tube with silica gel-coated surfacePlastic with sprayed nonsoluble silicaBiospecimen Aliquots and Components Biospecimen mixing Added Silica prior to blood collectionSilica added after separationBiospecimen Aliquots and Components Blood and blood products PlasmaSerum